Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Development of a nasal vaccine for chronic hepatitis B infection that uses the ability of hepatitis B core antigen to stimulate a strong Th1 response against hepatitis B surface antigen.

Aguilar JC, Lobaina Y, Muzio V, García D, Pentón E, Iglesias E, Pichardo D, Urquiza D, Rodríguez D, Silva D, Petrovsky N, Guillén G.

Immunol Cell Biol. 2004 Oct;82(5):539-46.

PMID:
15479440
2.

Hepatitis B surface antigen (HBsAg) and core antigen (HBcAg) combine CpG oligodeoxynucletides as a novel therapeutic vaccine for chronic hepatitis B infection.

Li J, Ge J, Ren S, Zhou T, Sun Y, Sun H, Gu Y, Huang H, Xu Z, Chen X, Xu X, Zhuang X, Song C, Jia F, Xu A, Yin X, Du SX.

Vaccine. 2015 Aug 20;33(35):4247-54. doi: 10.1016/j.vaccine.2015.03.079. Epub 2015 Apr 6.

PMID:
25858855
3.

Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus.

Akbar SM, Chen S, Al-Mahtab M, Abe M, Hiasa Y, Onji M.

Antiviral Res. 2012 Oct;96(1):59-64. doi: 10.1016/j.antiviral.2012.07.011. Epub 2012 Aug 1.

PMID:
22884884
4.

Heat shock protein gp96 enhances humoral and T cell responses, decreases Treg frequency and potentiates the anti-HBV activity in BALB/c and transgenic mice.

Wang S, Qiu L, Liu G, Li Y, Zhang X, Jin W, Gao GF, Kong X, Meng S.

Vaccine. 2011 Aug 26;29(37):6342-51. doi: 10.1016/j.vaccine.2011.05.008. Epub 2011 May 19.

PMID:
21600951
5.
6.

Oral administration of synthetic selenium nanoparticles induced robust Th1 cytokine pattern after HBs antigen vaccination in mouse model.

Mahdavi M, Mavandadnejad F, Yazdi MH, Faghfuri E, Hashemi H, Homayouni-Oreh S, Farhoudi R, Shahverdi AR.

J Infect Public Health. 2017 Jan - Feb;10(1):102-109. doi: 10.1016/j.jiph.2016.02.006. Epub 2016 Mar 23.

7.

Comparative study of the immunogenicity and immunoenhancing effects of two hepatitis B core antigen variants in mice by nasal administration.

Lobaina Y, Palenzuela D, García D, Rodríguez D, Pichardo D, Muzio V, Aguilar JC.

Vaccine. 2006 Apr 12;24 Suppl 2:S2-58-9.

PMID:
16823928
8.

Synthetic DNA immunogen encoding hepatitis B core antigen drives immune response in liver.

Obeng-Adjei N, Choo DK, Saini J, Yan J, Pankhong P, Parikh A, Chu JS, Weiner DB.

Cancer Gene Ther. 2012 Nov;19(11):779-87. doi: 10.1038/cgt.2012.61. Epub 2012 Oct 5.

9.

Lentiviral vector encoding ubiquitinated hepatitis B core antigen induces potent cellular immune responses and therapeutic immunity in HBV transgenic mice.

Dai S, Zhuo M, Song L, Chen X, Yu Y, Zang G, Tang Z.

Immunobiology. 2016 Jul;221(7):813-21. doi: 10.1016/j.imbio.2016.01.015. Epub 2016 Feb 2.

PMID:
26874581
10.

A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice.

Buchmann P, Dembek C, Kuklick L, Jäger C, Tedjokusumo R, von Freyend MJ, Drebber U, Janowicz Z, Melber K, Protzer U.

Vaccine. 2013 Feb 6;31(8):1197-203. doi: 10.1016/j.vaccine.2012.12.074. Epub 2013 Jan 7.

PMID:
23306359
11.

Enhancement of T helper type 1 immune responses against hepatitis B virus core antigen by PLGA nanoparticle vaccine delivery.

Chong CS, Cao M, Wong WW, Fischer KP, Addison WR, Kwon GS, Tyrrell DL, Samuel J.

J Control Release. 2005 Jan 20;102(1):85-99.

PMID:
15653136
13.

Efficacy of hepatitis B vaccine in the Gambian expanded programme on immunisation.

Fortuin M, Chotard J, Jack AD, Maine NP, Mendy M, Hall AJ, Inskip HM, George MO, Whittle HC.

Lancet. 1993 May 1;341(8853):1129-31.

PMID:
8097813
14.

Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens.

Betancourt AA, Delgado CA, Estévez ZC, Martínez JC, Ríos GV, Aureoles-Roselló SR, Zaldívar RA, Guzmán MA, Baile NF, Reyes PA, Ruano LO, Fernández AC, Lobaina-Matos Y, Fernández AD, Madrazo AI, Martínez MI, Baños ML, Alvarez NP, Baldo MD, Mestre RE, Pérez MV, Martínez ME, Escobar DA, Guanche MJ, Cáceres LM, Betancourt RS, Rando EH, Nieto GE, González VL, Rubido JC.

Int J Infect Dis. 2007 Sep;11(5):394-401. Epub 2007 Jan 24.

15.

A truncated C-terminal fragment of Mycobacterium tuberculosis HSP70 gene enhanced potency of HBV DNA vaccine.

Li X, Yang X, Li L, Liu H, Liu J.

Vaccine. 2006 Apr 12;24(16):3321-31. Epub 2006 Jan 19.

PMID:
16472546
16.

HBsAg, HBcAg, and combined HBsAg/HBcAg-based therapeutic vaccines in treating chronic hepatitis B virus infection.

Akbar SM, Al-Mahtab M, Uddin MH, Khan MS.

Hepatobiliary Pancreat Dis Int. 2013 Aug;12(4):363-9. Review.

PMID:
23924493
17.

Mucosal immunogenicity of the hepatitis B core antigen.

Lobaina Y, García D, Abreu N, Muzio V, Aguilar JC.

Biochem Biophys Res Commun. 2003 Jan 17;300(3):745-50.

PMID:
12507513
18.

DNA immunization with fusion of CTLA-4 to hepatitis B virus (HBV) core protein enhanced Th2 type responses and cleared HBV with an accelerated kinetic.

Yin Y, Wu C, Song J, Wang J, Zhang E, Liu H, Yang D, Chen X, Lu M, Xu Y.

PLoS One. 2011;6(7):e22524. doi: 10.1371/journal.pone.0022524. Epub 2011 Jul 22.

19.

[The immunization effects of HBV core antigen and surface antigen fusion protein in mice].

Li L, Tian YJ, Shen H, Zhao XP, Yang DL.

Zhonghua Gan Zang Bing Za Zhi. 2009 Apr;17(4):275-9. Chinese.

PMID:
19403026
20.

Immunological characterization of two hepatitis B core antigen variants and their immunoenhancing effect on co-delivered hepatitis B surface antigen.

Lobaina Y, Palenzuela D, Pichardo D, Muzio V, Guillén G, Aguilar JC.

Mol Immunol. 2005 Feb;42(3):289-94.

PMID:
15589316

Supplemental Content

Support Center